VNRX
AMEXVolitionRX Limited
Price$1.79-2.25 (-55.69%)
2026-03-042026-06-05
News · 26 weeks88-54%
2025-12-142026-06-07
Mix3490d
- SEC Filings14(41%)
- Other11(32%)
- Insider4(12%)
- Earnings4(12%)
- Offering1(3%)
Latest news
25 items- PRVolitionRx Announces Pricing of $4.6 Million Public Offering$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. T
- SECSEC Form 424B5 filed by VolitionRX Limited424B5 - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment MonitoringSeeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak ZonesHENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients who are suspected of having contracted the Ebola virus. Dr. Jake Micallef, Chief Scientific Officer, Volition commented:"This filing yet again shows the breadth of utility of our technology: it claims the potential use of Volition's existing Nu.Q® NETs test for Ebola. The Nu.Q® NETs test qua
- SECSEC Form DEF 14A filed by VolitionRX LimitedDEF 14A - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsUpdate Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic LeadersHENDERSON, Nev., May 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months. Key Highlights:First Quarter Revenue Growth: Reported $1M of revenue in the first quarter of 2026, representing a 300% increase year-over-year.Feline Lymphoma Manuscript Submission: Formally submitted the clinical manuscript for the
- SECVolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Leadership Update8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by VolitionRX LimitedSCHEDULE 13G/A - VOLITIONRX LTD (0000093314) (Subject)
- SECSEC Form 10-Q filed by VolitionRX Limited10-Q - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Limited Announces First Quarter 2026 Financial Results and Business UpdateConference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., May 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management will host a conference call tomorrow, May 15 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We have made strong progress across all of our product pillars during the first quarter and indeed s
- SECSEC Form PRE 14A filed by VolitionRX LimitedPRE 14A - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdateConference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., May 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2026 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call Date: Friday, May 15, 2026Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/Inter
- SECAmendment: SEC Form 10-K/A filed by VolitionRX Limited10-K/A - VOLITIONRX LTD (0000093314) (Filer)
- PRVolition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingHENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype. This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing. Volition has previously announced r
- SECVolitionRX Limited filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanHENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance for continued listing on the exchange. As previously reported, on February 6, 2026, the Company received a notice from the NYSE American stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses fro
- PRVolition Launches rNuQ™ Webshop Broadening Product RangeHENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we have developed over the past 10 years. We have developed a range of cutting edge controls for our own products, and they should be very useful in a range of research settings. Given our shift to commercialization, we are now opening up these for sale through an online offering.Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented:"We are delighted to launch our extensive range of off-the-shelf recombinant nucleosomes through this e
- SECVolitionRX Limited filed SEC Form 8-K: Other Events, Submission of Matters to a Vote of Security Holders8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - VOLITIONRX LTD (0000093314) (Filer)
- SECSEC Form 10-K filed by VolitionRX Limited10-K - VOLITIONRX LTD (0000093314) (Filer)
- SECVolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - VOLITIONRX LTD (0000093314) (Filer)
- PRVolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdateConference call to discuss financial and operational results scheduled forWednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025. Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of
- PRVolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A. ("WE") in Belgium. Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its regulatory transition program for Nu.Q® NETs (from IVDD to IVDR), the continued research and development of a Lateral Flow product, specifically to enable access to its Nu.Q® NETs product in Low Income Countries and more.Mr. Nicolas Delahaye, Corporate Relations Manager, Namur
VNRX FAQ
7 questionsWhat does VolitionRX Limited do?
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.Where does VNRX stock trade?
VolitionRX Limited (VNRX) is listed on AMEX.What sector and industry is VNRX in?
VolitionRX Limited operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did VolitionRX Limited go public?
VolitionRX Limited (VNRX) completed its IPO in 2015.What are analysts saying about VNRX?
VolitionRX Limited has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $250.00 price target on 2025-04-08. Recent price targets range from $250.00 to $900.00.What companies are similar to VNRX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare VNRX side-by-side with any of them on Quantisnow.How can I track VNRX on Quantisnow?
Quantisnow aggregates VolitionRX Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VNRX to receive live email and push alerts on every new disclosure.